Skip to main content
Retour
Watch Compare

Traws Pharma, Inc.

Qualité des données : 100%
TRAW
NASDAQ Manufacturing Chemicals
1,21 €
▼ 0,02 € (-1,63%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-0,55%

Croissance

Revenue Growth (5Y)
-0,55%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-207,84%
En dessous de la moyenne du secteur (-54,47%)
ROIC-194,45%
Net Margin-467,64%
Op. Margin-554,64%

Sécurité

Debt / Equity
N/A
Current Ratio1,22
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,90 | -0,40
Au-dessus de la moyenne du secteur (-1,50)
P/B Ratio2,62
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -0,55% annually over 5 years
Negative free cash flow of -19,47 M
Capital efficient — spends only 0,00% of revenue on capex

Price History

Tendances Financières

Objectif de Cours des Analystes

2 analystes
Buy
+354.5%
upside to target
Actuel
1,21 €
Consensus Target
5,50 €
3,00 €
Bas
8,00 €
Haut
Prévisions
P/E Prévisionnel
-0,40
BPA Prévisionnel
-3,09 €
CA Est.
13,10 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,51 € · Rev Est: 0,0
Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,34 € -0,55 € — —
Estimate — -0,54 € -0,51 € -0,59 €
Surprise — -2,67% — —

Growth

Rev 5Y: -0,55% · Earnings 1Y: N/A
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 0,00%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0,55% Earnings Growth (5Y) N/A

Profitability

ROE: -207,84% · Net Margin: -467,64%
Revenue (TTM) 2,85 M Net Income (TTM) -13,31 M
ROE -207,84% ROA -94,84%
Gross Margin N/A Operating Margin -554,64%
Net Margin -467,64% Free Cash Flow (TTM) -19,47 M
ROIC -194,45% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1,22
Debt / Equity N/A Current Ratio 1,22
Interest Coverage N/A Asset Turnover 0,20
Working Capital 1,74 M Tangible Book Value 1,97 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,90 · EV/EBITDA: N/A
P/E Ratio -0,90 Forward P/E -0,40
P/B Ratio 2,62 P/S Ratio 4,19
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0,91 Fwd Earnings Yield N/A
FCF Yield -163,22%
Market Cap 11,93 M Enterprise Value 11,93 M

Per Share

EPS: 97,19 · FCF/Share: -2,44
EPS (Diluted TTM) 97,19 Revenue / Share 0,36
FCF / Share -2,44 OCF / Share -2,44
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 146,27% · CapEx/Rev: 0,00%
CapEx / Revenue 0,00% FCF Conversion 146,27%
SBC-Adj. FCF -20,21 M Growth Momentum 0,55

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022 FY2019
Revenue 226 000,0 226 000,0 226 000,0 226 000,0 2,18 M
Net Income -166,52 M -18,95 M -16,16 M -18,96 M -21,50 M
EPS (Diluted) -35,21 -0,90 -0,96 -0,91 —
Gross Profit — — — — —
Operating Income -142,37 M -20,30 M -16,50 M -19,63 M -21,70 M
EBITDA — — — — —
R&D Expenses — 11,43 M 7,30 M 11,41 M 15,54 M
SG&A Expenses — — — — —
D&A 12 000,0 16 000,0 14 000,0 14 000,0 14 000,0
Interest Expense — — — — —
Income Tax — — 4 000,0 — 10 000,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022 FY2019
Total Assets 24,96 M 22,68 M 55,48 M 39,37 M 23,67 M
Total Liabilities 56,59 M 12,01 M 9,36 M 11,06 M 12,10 M
Shareholders' Equity -31,63 M 10,67 M 46,12 M 28,31 M 11,57 M
Total Debt — — — — —
Cash & Equivalents — 20,56 M — 38,52 M —
Current Assets 24,95 M 22,66 M 55,43 M 39,35 M 23,47 M
Current Liabilities 11,53 M 9,22 M 6,12 M 8,05 M 8,29 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,9 -1,5
P/B 2,6 1,6
ROE % -207,8 -54,5
Net Margin % -467,6 -41,5
Rev Growth 5Y % -0,6 1,8
D/E — 0,3